Skip to content

 

Why partner with us

Gain key insights icon

Gain key insights into disease mechanisms and factors driving patient response

Uncover patient stratification icon

Uncover patient stratification biomarkers for recruitment criteria informing clinical trial design

Create complementary diagnostics icon

Create complementary diagnostics for treatments with responder stratification biomarkers

Add value to R and D programs

Add value to R&D programs with retrospective analysis to identify drug response biomarkers

Partnering with us

 

Inform and derisk your clinical development

7.SJOGRENS-min

Prospective analysis

Our prospective clinical trial analysis identifies the combinations of genetic and non-genetic features responsible for individual disease subtypes, enabling you to design smaller, faster to read out clinical trials targeted at your drug’s mechanism.

3.COPD-min

Retrospective analysis

Our retrospective analysis of clinical trial datasets that have not returned clear enough efficacy signal identifies drug response biomarkers that clearly delineate responders from non-responders to inform strategy and enable future trial success.

Biomarker-driven development

Our CTAx solutions provide easy-to-implement patient stratification biomarkers for inclusion criteria to design better targeted clinical trials containing more responders, which can be smaller and faster to read out.

And these same biomarkers are also used as complementary diagnostic tools to enable fast launch of new products and support a desired price point by demonstrating high response rates.

5. Endometriosis-01-min
Distinguish responders vs non-responders2-min

Distinguish responders vs. non-responders with high-resolution patient stratification

We help you avoid the considerable costs associated with clinical trial failure while also reducing the costs of running successful programs with faster, more focused trials.

Our proprietary method for stratifying patients whose disease is mediated by the drug candidate’s mechanism of action identifies responders, decreasing cohort sizes and recruitment times necessary to obtain statistical validation of the efficacy of new treatments.

Maximize value from trials

Recover sunk costs with our retrospective analysis of patient cohorts from trials that previously failed to demonstrate sufficient efficacy.

We generate patient stratification biomarkers from retrospective analysis of Phase III clinical trials to identify the features that differentiate patients who show a strong drug response. These insights maximize the opportunity for clinical trial success and avoid the primary causes of an original study’s failure in follow-up trials.

Alz stratification-min
Accelerate market adoption-min

Accelerate market adoption

The benefits of using our approach do not end at regulatory approval. The same stratification biomarkers provide an easy means for clinicians to identify the people most likely to benefit from your approved treatment, ensuring that it’s adopted quickly and prescribed to the people who need it most.

Benefits of our unique approach

Many late-stage drug trials fail due to an inability to demonstrate clinical efficacy, incurring huge expense, disruption and impact on company value. This is often due to suboptimal study design and recruitment rather than a lack of drug effectiveness.

We are uniquely able to perform high-resolution patient stratification for complex diseases, disentangling the combinations of genes, pathways, and environmental factors that interact to determine a patient’s drug response.

By analyzing the level of drug response as a quantitative trait, we are able to identify the combination of features associated with strong drug responders. These drug response biomarkers can be used with regulators, to refine clinical trial design, and also as complementary diagnostic tools to support new therapeutic product launches.

Target your clinical trials for success

Identify drug response biomarkers and recruit patients who respond favorably to your drug candidates in late-stage trials to demonstrate efficacy even in clinical programs that have previously failed

Contact us